New imaging technique could reveal how cancer drugs target tumors
NCT ID NCT07440212
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test a new type of PET scan that uses a radioactive tag to track an experimental antibody (ivonescimab) in people with esophageal cancer. The goal is to see where the antibody goes in the body and how well it targets tumors, which could help doctors choose the right treatments. About 50 adults with esophageal cancer will receive the tagged antibody and then have PET scans to measure its distribution. The study does not treat the cancer but aims to improve how we monitor and predict treatment response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Daping Hospital, Army Medical University
Chongqing, Chongqing Municipality, 400010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized radiation pulses could boost esophageal cancer treatment
- Can a condensed radiation blast plus chemo keep esophageal cancer at bay?
- New proton combo aims to improve esophageal cancer treatment
- New drug combo aims to stop Chemo-Induced nausea in cancer patients
- Remote exercise program aims to boost chemo completion in cancer patients
- New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers